{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:43:47Z","timestamp":1790408627707,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"am","delay-in-days":315,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021564","name":"Unicancer","doi-asserted-by":"publisher","award":["NCT02363751"],"award-info":[{"award-number":["NCT02363751"]}],"id":[{"id":"10.13039\/501100021564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ejca.2023.03.018","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T18:35:34Z","timestamp":1679596534000},"page":"83-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG\/AFU24)"],"prefix":"10.1016","volume":"186","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-1341","authenticated-orcid":false,"given":"Constance","family":"Thibault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Fl\u00e9chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Barthelemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Gross-Goupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Chevreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Coquan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6957-0894","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Laguerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenaelle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"P\u00e9cuchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9za-Thierry","family":"Elaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Olivier","family":"Timsit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryem","family":"Brihoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Auclin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"de Reyni\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5526-077X","authenticated-orcid":false,"given":"Yves","family":"Allory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.03.018_bib1","first-page":"54","article-title":"Collecting duct carcinoma of kidney","volume":"15","author":"Srigley","year":"1998","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.ejca.2023.03.018_bib2","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1365-2559.1986.tb02553.x","article-title":"Collecting duct carcinoma of the kidney","volume":"10","author":"Fleming","year":"1986","journal-title":"Histopathology"},{"key":"10.1016\/j.ejca.2023.03.018_bib3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00428-004-1124-z","article-title":"Collecting duct carcinoma: an entity to be redefined","volume":"445","author":"Kaf\u00e9","year":"2004","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ejca.2023.03.018_bib4","unstructured":"H\u00a0M,\u00a0PA\u00a0H,\u00a0TM\u00a0U,\u00a0VE\u00a0R.\u00a0WHO classification of tumours of the urinary system and male genital organs. n.d."},{"key":"10.1016\/j.ejca.2023.03.018_bib5","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2559.2011.04093.x","article-title":"p63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system","volume":"60","author":"Carvalho","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.ejca.2023.03.018_bib6","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/PAS.0b013e3182770406","article-title":"Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation","volume":"37","author":"Liu","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejca.2023.03.018_bib7","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.3816\/CGC.2009.n.017","article-title":"Influence of demographic factors on outcome of collecting duct carcinoma: a Surveillance, Epidemiology, and End Results (SEER) database analysis","volume":"7","author":"Pepek","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ejca.2023.03.018_bib8","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.5489\/cuaj.2373","article-title":"Clinical outcome and prognostic factors in renal medullary carcinoma: a pooled analysis from 18 years of medical literature","volume":"9","author":"Iacovelli","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.ejca.2023.03.018_bib9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0022-5347(06)00502-7","article-title":"Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan","volume":"176","author":"Tokuda","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2023.03.018_bib10","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.eururo.2007.01.070","article-title":"Collecting duct renal cell carcinoma: a matched analysis of 41 cases","volume":"52","author":"Karakiewicz","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2023.03.018_bib11","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.3747\/co.20.1230","article-title":"Management of renal collecting duct carcinoma: a systematic review and the McMaster experience","volume":"20","author":"Dason","year":"2013","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ejca.2023.03.018_bib12","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2002.11.123","article-title":"Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.03.018_bib13","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/annonc\/mdt578","article-title":"Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies","volume":"25","author":"Voss","year":"2014","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2023.03.018_bib14","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.eururo.2012.06.043","article-title":"A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma","volume":"62","author":"Tannir","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2023.03.018_bib15","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.03.018_bib16","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.juro.2007.01.063","article-title":"Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d\u2032Etudes des Tumeurs Uro-G\u00e9nitales) study","volume":"177","author":"Oudard","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2023.03.018_bib17","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1200\/JCO.2012.42.5215","article-title":"Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer","volume":"31","author":"Balar","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.03.018_bib18","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1200\/JCO.2010.31.6067","article-title":"Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75","volume":"29","author":"Hahn","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.03.018_bib19","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1093\/annonc\/mdt423","article-title":"Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma","volume":"24","author":"P\u00e9cuchet","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.03.018_bib20","first-page":"1","article-title":"Updated recommendations on the diagnosis, management, and clinical trial eligibility criteria for patients with renal medullary carcinoma","volume":"17","author":"Msaouel","year":"2019","journal-title":"Clin\u00a0Genitourin\u00a0Cancer"},{"key":"10.1016\/j.ejca.2023.03.018_bib21","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1001\/jamaoncol.2022.0238","article-title":"Cabozantinib as first-line treatment in patients with metastatic collecting duct renal cell carcinoma: results of the BONSAI trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 study)","volume":"8","author":"Procopio","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2023.03.018_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.04.007","article-title":"Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: a prospective, multicentre, single-arm, phase 2 study","volume":"100","author":"Sheng","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.03.018_bib23","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.03.018_bib24","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.21.00286","article-title":"Randomized phase III trial of gemcitabine and cisplatin with bevacizumab or placebo in patients with advanced urothelial carcinoma: results of CALGB 90601 (Alliance)","volume":"39","author":"Rosenberg","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.03.018_bib25","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.eururo.2015.06.019","article-title":"Characterization of\u00a0clinical cases of collecting duct carcinoma of the kidney assessed by comprehensive genomic profiling","volume":"70","author":"Pal","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2023.03.018_bib26","first-page":"30988","article-title":"Unique transcriptomic profile of collecting duct carcinomas relative to upper tract urothelial carcinomas and other kidney carcinomas","volume":"6","author":"Malouf","year":"2016","journal-title":"Sci\u00a0Rep"},{"key":"10.1016\/j.ejca.2023.03.018_bib27","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/annonc\/mdu445","article-title":"PD-L1 expression in nonclear-cell renal cell carcinoma","volume":"25","author":"Choueiri","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.03.018_bib28","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/j.clgc.2016.02.013","article-title":"Anti-programmed death receptor 1 blockade induces clinical response in a patient with metastatic collecting duct carcinoma","volume":"14","author":"Rimar","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ejca.2023.03.018_bib29","first-page":"988","article-title":"Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: a case report","volume":"7","author":"Mizutani","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.ejca.2023.03.018_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013173","article-title":"Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy: a case report","volume":"97","author":"Yasuoka","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ejca.2023.03.018_bib31","first-page":"9","article-title":"Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma","volume":"6","author":"Koshkin","year":"2018","journal-title":"J\u00a0ImmunoTher\u00a0Cancer"},{"key":"10.1016\/j.ejca.2023.03.018_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.04.002","article-title":"Comprehensive molecular characterization identifies distinct genomic and immune hallmarks of renal medullary carcinoma","volume":"37","author":"Msaouel","year":"2020","journal-title":"Cancer Cell"},{"issue":"Suppl. 4","key":"10.1016\/j.ejca.2023.03.018_bib33","article-title":"Metastatic renal medullary and collecting duct carcinoma in the era of antiangiogenic and immune checkpoint inhibitors: a multicentric retrospective study","volume":"31","author":"Guillaume","year":"2020","journal-title":"Ann\u00a0Oncol"},{"issue":"Suppl. 4","key":"10.1016\/j.ejca.2023.03.018_bib34","first-page":"S1142","article-title":"Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in na\u00efve metastatic kidney cancer (m-ccRCC) patients (pts): the BIONIKK trial","volume":"31","author":"Vano","year":"2020","journal-title":"Ann\u00a0Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:40:03Z","timestamp":1760733603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923001545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":34,"alternative-id":["S0959804923001545"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.03.018","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG\/AFU24)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}